Jianjing Hou

ORCID: 0000-0001-5213-2716
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Cancer Treatment Studies
  • Ferroptosis and cancer prognosis
  • Extracellular vesicles in disease
  • HER2/EGFR in Cancer Research
  • melanin and skin pigmentation
  • Radiomics and Machine Learning in Medical Imaging
  • Nanoplatforms for cancer theranostics
  • RNA Interference and Gene Delivery
  • Cytokine Signaling Pathways and Interactions
  • Cancer Mechanisms and Therapy
  • MicroRNA in disease regulation
  • Breast Implant and Reconstruction
  • Bioactive Compounds and Antitumor Agents
  • Circular RNAs in diseases
  • BRCA gene mutations in cancer
  • Angiogenesis and VEGF in Cancer
  • Reconstructive Surgery and Microvascular Techniques
  • Cancer-related molecular mechanisms research
  • Cancer Genomics and Diagnostics

Fudan University Shanghai Cancer Center
2020-2025

Shanghai Medical College of Fudan University
2021-2023

Shanghai Cancer Institute
2016-2021

State Key Laboratory of Oncogene and Related Genes
2016-2021

Renji Hospital
2016-2021

Abstract A large number RNAs are enriched and stable in extracellular vesicles (EVs), they can reflect their tissue origins suitable as liquid biopsy markers for cancer diagnosis treatment efficacy prediction. In this study, we used vesicle long RNA (exLR) sequencing to characterize the plasma-derived exLRs from 112 breast patients, 19 benign patients 41 healthy participants. The different profiling was found between non-cancer groups. Thus, constructed a diagnostic signature which showed...

10.1038/s41523-021-00356-z article EN cc-by npj Breast Cancer 2021-12-10

Introduction Despite its therapeutic advantages, postmastectomy radiotherapy (PMRT) increases the risk of complications and often leads to poor cosmesis in women undergoing breast reconstruction. Preoperative followed by skin-sparing mastectomy deep inferior epigastric perforator (DIEP) flap reconstruction is technically feasible, with low rates surgical good short-term oncological outcomes. Further evaluation a randomised trial comparing preoperative versus conventional PMRT required assess...

10.1136/bmjopen-2024-086980 article EN cc-by-nc-nd BMJ Open 2025-01-01

Hepatocellular carcinoma (HCC) is a common cause of cancer-related death worldwide, and its incidence continues to increase. However, the mechanism underlying development progression HCC remains unknown. The suppressor cytokine signaling 2 (SOCS2) member SOCS family influences carcinogenesis multiple types tumors, but biological roles SOCS2 in remain unclear. In this study, we found that expression was reduced tissues compared with matched noncancerous liver tissues. Moreover, decreased...

10.1007/s13277-016-5215-7 article EN Tumor Biology 2016-07-27

Pigment epithelium-derived factor (PEDF) has complex functions in tumor metastasis, but little is known about the roles of PEDF and its receptors hepatocellular carcinoma (HCC). Here we found that high expression associated with shorter overall survival HCC patients. Forced enhanced cell aggressive behavior vitro vivo, whereas silencing reduced migration invasion. Furthermore, led to changes morphology epithelial-mesenchymal transition (EMT)-related markers via ERK1/2 signaling pathway,...

10.1038/cddis.2017.359 article EN cc-by Cell Death and Disease 2017-08-03

Aim: This retrospective study aimed to evaluate the effect of age on cancer relapse and survival in breast patients undergoing different treatments. Methods: The propensity score method was used correct for disparities between two groups; 2049 young were matched 4053 older patients. Kaplan-Meier curves Cox proportional hazards models assess disease-free survival. Results: In original cohort, showed higher lymph node metastasis, hormone-receptor positivity high Ki-67 levels. After matching,...

10.2217/fon-2023-0083 article EN Future Oncology 2023-03-01

Abstract Background: Female breast cancer has been the world’s leading incidence among women. HER2-positive accounts for about 15%~20% of all cancer, with a high degree malignancy and easy metastasis recurrence. With development medical technology continuous innovation HER2 targeting drugs, patients have more treatment options their prognosis had greatly improved. However, there is still lack biomarkers early in clinical practice. Methods: This study prospectively collected single-center...

10.1158/1538-7445.sabcs22-p2-16-04 article EN Cancer Research 2023-03-01

Abstract Background: The utility of extracellular vesicle long RNAs (exLRs) as noninvasive biomarkers in breast cancer remains elusive. purpose this study was to explore the potential exLRs clinically actionable for diagnosis, classification, and neoadjuvant therapy efficacy prediction. Methods: One hundred seventy-two participants, including 112 patients, 19 benign patients 41 healthy controls, were enrolled case-control study. exLR profile plasma samples analyzed by sequencing. d-signature...

10.21203/rs.3.rs-111007/v1 preprint EN cc-by Research Square (Research Square) 2020-11-20

Abstract Purpose: To compare the time-varying recurrence patterns of different molecular subtypes breast cancer in contemporary era with those past era. Methods: This retrospective study included 14627 consecutive invasive patients who underwent surgery from 2008 to 2016 at Fudan University Shanghai Cancer Center. We defined period 2013 as and that 2012 Five were according immunohistochemistry results. Emphasis was made on changing for changed between two treatment eras. Kaplan–Meier...

10.21203/rs.3.rs-1750796/v1 preprint EN cc-by Research Square (Research Square) 2022-06-21

Following publication of this article it was noted that there were errors in figures 4 and 6.In figure 4a, the β-actin control same as used Figure 6d, addition, ERK1/2 4a flipped horizontally.In 6a, two migration images MHCC-97L cells chosen by mistake, invasion Huh 7 6a.The corrected are shown below.This correction does not change description, interpretation, or original conclusions manuscript.The authors apologize for any inconvenience caused.

10.1038/s41419-021-03975-3 article EN cc-by Cell Death and Disease 2021-07-20
Coming Soon ...